Compare Colgate-Palmolive Company (CL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Colgate-Palmolive Company vs Novo Nordisk A/S — how do they compare? Colgate-Palmolive Company trades at $90.95 (market cap $74.59B), while Novo Nordisk A/S trades at $49.09 (market cap $218.15B). The key difference: Novo Nordisk A/S is far larger — about 2.9× Colgate-Palmolive Company's market cap, and Novo Nordisk A/S pays the higher dividend (3.66%). Which is the better fit depends on your goals.
| CL | NVO | |
|---|---|---|
Market Cap | $74.59B | $218.15B |
Sector | Consumer Staples | Health |
52-Week High | $99.14 | $71.70 |
52-Week Low | $74.98 | $35.29 |
Enterprise Value | $81.22B | $237.11B |
Dividend Yield | 2.27% | 3.66% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
